Unlike in situ carcinomas of other organs, transitional-cell carcinoma in situ (CIS) of the bladder is a highly aggressive, potentially life-threatening malignancy. The recognized lethality of CIS, and the general ineffectiveness of such treatment options as transurethral fulguration, radiation therapy, and intravesical chemotherapy, led to the use of radical cystectomy as the treatment of choice.
In 1990, based on a Southwest Oncology Group (SWOG) comparison of TheraCys (Connaught) bacillus Calmette-Guérin (BCG) vs doxorubicin chemotherapy and six studies of Tice (Organon) BCG, the FDA approved BCG for the treatment of CIS. Continued experience confirms that intravesical BCG immunotherapy is now the initial treatment of choice for patients with CIS and that cystectomy can be safely reserved for the minority of patients who fail to respond completely to intravesical therapy.
This review will summarize BCG immunotherapy for CIS, specifically discussing treatment techniques, results, adverse reactions, and alternative immunotherapeutic strategies. As background to this discussion, a brief overview of transitional-cell CIS will be provided.
Carcinoma in situ of the bladder was first described in 1952 by Melicow . The diffuse nature of CIS was demonstrated in a subsequent report of 30 cases in which CIS extended from the renal pelvis to the penile urethra . Carcinoma in situ may occur as a primary disease, in association with papillary or solid tumors, or following tumor resection.
Irritative symptoms are common in patients with primary or concurrent CIS . Hematuria also is a frequent presenting feature. Urinary cytology is positive in more than 90% of patients with CIS and is an important diagnostic procedure because cystoscopic findings and even bladder biopsy may be falsely negative.
The clinical course of CIS is highly variable, but overall, prior to the advent of BCG immunotherapy, 54% of patients progressed to muscle-invasive disease . Extensive, diffuse disease is considered to pose an increased risk for progression, whereas focal disease may exist for years and has a reported incidence of progression as low as 8% .
Focal CIS is the earliest stage in the evolution of invasive bladder cancer, and although its course is often protracted, regression virtually never occurs. Patients with focal disease are optimal candidates for intravesical therapy.
Diffuse, widespread disease is typically associated with irritative symptoms, and up to 34% of patients treated with cystectomy will be found to have unsuspected microinvasive carcinoma . In situ disease extends to the distal ureter in as many as 57% of patients and to the prostatic urethra in as many as 62% . Despite cystectomy, death from metastatic disease occurs in up to 6% of high-risk CIS patients.
Radiation and Systemic Chemotherapy
The results of radiation therapy for CIS are disappointing. In a series of 11 patients treated with external-beam radiation therapy, 10 (91%) died at a mean follow-up of 3.5 years . Similarly, although systemic chemotherapy may temporarily eradicate CIS, local recurrence is a virtual certainty.
The results of topical intravesical chemotherapy have been much more encouraging, and this treatment modality continues to have a role in the management of CIS. In a review of 448 patients treated with intravesical chemotherapy, the overall complete response rate averaged 48%. Complete responses were reported in 38% of 89 patients treated with thiotepa (Thiotepa), 48% of 212 patients treated with doxorubicin, and 53% of 147 patients treated with mitomycin (Mutamycin) .
In most series, fewer than 20% of patients treated with intravesical chemotherapy remain disease free for 5 years or more, but preliminary encouraging results have been reported with the combination of mitomycin and doxorubicin followed by maintenance chemotherapy . In the absence of a clear indication for intravesical chemotherapy (ie, suspected or confirmed residual disease), unnecessary instillations should be avoided, as repeated instillation of thiotepa, doxorubicin, or mitomycin in normal rodent bladders reportedly induces atypia, CIS, and even invasive transitional-cell carcinoma .
1. Melicow MM: Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 68:261, 1952.
2. Melicow MM, Hollowell JW: Intra-urothelial cancer: Carcinoma in situ, Bowen's disease of the urinary system: Discussion of 30 cases. J Urol 147:11, 1952.
3. Okaneya T, Ikado S, Ogawa A: The progress pattern of carcinoma in situ of the urinary bladder. Nippon Hinyokika Gakkai-Zasshi 82:1227-1232, 1991.
4. Lamm DL: Carcinoma in situ, in Lamm DL (ed): The Urologic Clinics Of North America, vol 19, pp 499-508. Philadelphia, WB Saunders, 1992.
5. Riddle PR, Chism GD, Trott PA, et al: Flat carcinoma in situ of bladder. Br J Urol 47:829, 1976.
6. Utz DC, Farrow DM: Carcinoma in situ of the urinary tract. Urol Clin North Am 11:735, 1984.
7. Fukui I, Kihara K, Sekine H, et al: Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: A randomized trial of maintenance versus no maintenance following a complete response, Cancer Chemother Pharmacol 30:37-40, 1992.
8. Friedman D, Mooppan UM, Rosen Y, et al: The effect of intravesical instillations of thiotepa, mitomycin C and adriamycin on normal urothelium: An experimental study in rats. J Urol 145:1060-1063, 1991.
9. Holmgren I: Tuberculine it le BCG chez les cancereuz. Schwiez Med Wochenschr 65:1203-1206, 1935.
10. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180, 1976.
11. Davies M: Bacillus Calmette-Guérin as an antitumor agent: The interaction with cells of the mammalian immune system. Biochem Biophys Acta 651:143, 1982.
12. Sosnowski JT, Lamm DL: Immunotherapy for bladder cancer, in Rous SN (ed): Urology Annual, vol 4, pp 123-156. East Norwalk, Connecticut, Appleton & Lange, 1990.
13. Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136:970, 1986.
14. Morales A, Ottenhof PC: Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 52:667, 1983.
15. Ratliff TL, Gillen D, Catalona WJ: Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155, 1987.
16. Bohle A, Thanhauser A, Ulmer AJ, et al: Dissecting the immunobiological effects of Bacillus Calmette-Guerin in vitro: Evidence of a distinct BCG activated killer (BAK) cell phenomenon. J Urol 150:1032, 1993.
17. Ratliff TL, Hudson MA, Catalona WJ: Strategy for improving therapy of superficial bladder cancer. World J Urol 9:95, 1991.
18. Becich MJ, Carroll S, Ratliff TL: Internalization of Bacille Calmette-Guérin by bladder tumor cells. J Urol 145:1316, 1991.
19. Morales A, Nickel JC: Immunotherapy of superficial bladder cancer with BCG. World J Urol 3:209, 1986.
20. Garden RJ, Liu BCS, Redwood SM, et al: Bacillus Calmette-Guérin abrogates in vitro invasion and motility of human bladder tumor cells via fibronectin interaction. J Urol 148:900, 1992.
21. Herr HW, Laudone VP, Whitmore WF: An overview of intravesical therapy for superficial bladder tumors. J Urol 138:1363, 1987.
22. Lamm DL, Riggs DR, Traynelis CL, et al: Failure of current intravesical chemotherapy prophylaxis in superficial transitional-cell carcinoma of the bladder. J Urol, 153:1444, 1995.
23. Herr HW, Laudone VP, Badalament RA, et al: Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6:1450, 1988.
24. Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors, in Fair WR (ed): The Urologic Clinics of North America, vol 18, pp 525-528. Philadelphia, WB Saunders, 1991.
25. Lamm DL, Blumenstein BA, Crawford ED, et al: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205, 1991.
26. Pagano F, Bassi P, Milani C, et al: A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: Is it effective? J Urol 146:32, 1991.
27. Bast RC Jr, Zbar B, Borsos T, et al: BCG and cancer 1. N Engl J Med 290:1413, 1974.
28. Lamm DL, Reichert DF, Harris SC, et al: Immunotherapy of murine transitional cell carcinoma. J Urol 128:1107, 1982.
29. Morales A, Nickel JC, Wilson JWL: Dose response of Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J Urol 147:1256, 1992.
30. Pagano F, Bassi P, Piazza N, et al: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 27(suppl 1).:19-22, 1995.
31. Ratliff TL, Kavoussi LR, and Catalona WJ: Role of fibronectin in intravesical bcg therapy for superficial bladder cancer. J Urol 139:410-414, 1988.
32. Hudson MA, Yvan JJ, Catalona WJ, et al: Adverse effect of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors. J Urol 144:1362-1364, 1990.
33. Rogerson JW: Intravesical bacille Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder. Br J Urol 73:655-658, 1994.
34. Lamm DL, Crawford ED, Blumenstein B, et al: Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group Study. J Urol 147:4(242), 1992.
35. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134:40, 1985.
36. Badalament RA, Herr HW, Wong GY, et al: A prospective randomized trial of maintenance versus nonmaintenance intravesical Bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 5:441, 1987.
37. Hudson MA, Ratliff TL, Gillen DP, et al: Single course versus maintenance Bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective, randomized trial. J Urol 138:295, 1987.
38. Marcus SL, Petrylak DP, Dutcher JP, et al: Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells, Am J Clin Nutr 54:1292s-1297s, 1991.
39. Baker H, Marcus SL, Petrylak DP, et al: Effect of interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers. J Am Col Nutr 11:482-486, 1992.
40. Lamm DL, Riggs DR, Shriver JS, et al : Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151:21-26, 1994.
41. Lamm DL: Complications of Bacillus Calmette-Guerin Immunotherapy, Urol Clin N Am 19:565-572, 1992.
42. Sargent ER and Williams RD: Immunotherapeutic alternatives in superficial bladder cancer. Urol Clin N Amer 19:581-589, 1992.
43. Grups J, Frohmuller H, Ackermann R: Can recombinant human gamma-2 interferon prevent recurrence of high-grade superficial bladder tumors? Cancer Detect Prev 10:405, 1987.
44. Torti F. Shortliffe L, Williams R, et al: Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group study. J Clin Oncol 6:476, 1988.
45. Glashan R: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144:658, 1990.
46. Kalble T, Beer M, Staehler G: Intravesical prophylaxis with BCG vs interferon A for superficial bladder cancer. J Urol 151:22(233a), 1994.
47. Olsson CA, Chute R, Rao CN: Immunologic reduction of bladder cancer recurrence rate. J Urol 111:173, 1974.
48. Jurincic C, Engelmann U, Gasch J: Immunotherapy in bladder cancer with Keyhole-Limpet hemocyanin: a randomized study. J Urol 139:723, 1988.
49. Flamm, J, Bucher A, Holtl W: Recurrent superficial transitional cell carcinoma of the bladder: Adjuvant topical chemotherapy versus immunotherapy: A prospective randomized trial J Urol 144:260, 1990.
50. Rios A, Stringfellow DA, Fitzpatrick FA, et al: Phase study of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP), an oral interferon inducer in cancer patients. J Biol Resp Modifiers 5:330-338, 1986.
51. Simmons WB, Reichert DF, Lucio RM, et al: Pyrimidinone interferon inducers in the treatment of murine transitional cell carcinoma. J Urol 130:169(309), 1983.